Introduction: In a 24-hour porcine model of liver injury, we showed that fibrinogen supplementation does not downregulate endogenous fibrinogen synthesis. Herewe report data from the same study showing the impact of fibrinogen on coagulation variables. Materials and Methods: Coagulopathy was induced in 20 German land race pigs by hemodilution and blunt liver injury. Animals randomly received fibrinogen concentrate (100 mg/kg) or saline. Coagulation parameters were assessed and thromboelastometry (ROTEM) was performed. Results: Fibrinogen concentrate significantly reduced the prolongations of EXTEM clotting time, EXTE
BACKGROUND: Recombinant factor VIIa (rFVIIa) has been used to decrease bleeding in a number of setti...
Aim: To evaluate coagulofibrinolytic abnormalities and the effects of ART-123 (recombinant human thr...
Background: Optimal hemostatic management during orthotopic liver transplantation (OLT) remains a ch...
Fibrinogen substitution is an established therapeutic element in the treatment of patients with fulm...
BACKGROUND: The potential clinical benefits of targeted therapy with coagulation factor concentrates...
Background. This study was conducted to determine whether replacement of fibrinogen is useful in rev...
Despite increasing use of prothrombin complex concentrate (PCC) to treat hemorrhage-associated coagu...
ObjectivesDilutional coagulopathy after resuscitation with crystalloids/colloids clinically often ap...
Objective of the study is to experimentally evaluate system hemostatic and prothrombotic effects of ...
Abstract Background Serious injuries accompanied by severe bleeding are life-threatening. Post-traum...
Although prothrombin complex concentrate (PCC) is increasingly used for the treatment of trauma-indu...
Recombinant factor VIIa (rFVIIa) is registered for use in haemophilia with inhibitors and other rare...
Background Recombinant factor VIIa (rFVIIa) is registered for use in haemophilia with inhibitors and...
Recombinant factor VIIa (rFVIIa) is registered for use in haemophilia with inhibitors and other rare...
Animal models are widely used in research on blood coagulation and fibrinolysis, and the choice of a...
BACKGROUND: Recombinant factor VIIa (rFVIIa) has been used to decrease bleeding in a number of setti...
Aim: To evaluate coagulofibrinolytic abnormalities and the effects of ART-123 (recombinant human thr...
Background: Optimal hemostatic management during orthotopic liver transplantation (OLT) remains a ch...
Fibrinogen substitution is an established therapeutic element in the treatment of patients with fulm...
BACKGROUND: The potential clinical benefits of targeted therapy with coagulation factor concentrates...
Background. This study was conducted to determine whether replacement of fibrinogen is useful in rev...
Despite increasing use of prothrombin complex concentrate (PCC) to treat hemorrhage-associated coagu...
ObjectivesDilutional coagulopathy after resuscitation with crystalloids/colloids clinically often ap...
Objective of the study is to experimentally evaluate system hemostatic and prothrombotic effects of ...
Abstract Background Serious injuries accompanied by severe bleeding are life-threatening. Post-traum...
Although prothrombin complex concentrate (PCC) is increasingly used for the treatment of trauma-indu...
Recombinant factor VIIa (rFVIIa) is registered for use in haemophilia with inhibitors and other rare...
Background Recombinant factor VIIa (rFVIIa) is registered for use in haemophilia with inhibitors and...
Recombinant factor VIIa (rFVIIa) is registered for use in haemophilia with inhibitors and other rare...
Animal models are widely used in research on blood coagulation and fibrinolysis, and the choice of a...
BACKGROUND: Recombinant factor VIIa (rFVIIa) has been used to decrease bleeding in a number of setti...
Aim: To evaluate coagulofibrinolytic abnormalities and the effects of ART-123 (recombinant human thr...
Background: Optimal hemostatic management during orthotopic liver transplantation (OLT) remains a ch...